Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - buprenorphine, quantity: 30 mg - patch, dermal - excipient ingredients: oleyl oleate; polyethylene; povidone; levulinic acid; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; butyl acrylate; acrylic acid; 2,2'-azobisisobutyronitrile; aluminium acetylacetonate; heptane; acrylates copolymer; ethylene distearamide; adipic acid/1,4-butanediol/mdi copolymer; pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate - buprenorphine sandoz patches are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. buprenorphine sandoz patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. buprenorphine sandoz patches are not indicated as an as-needed (prn) analgesia.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - buprenorphine, quantity: 25 mg - patch, dermal - excipient ingredients: oleyl oleate; polyethylene; povidone; levulinic acid; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; butyl acrylate; acrylic acid; 2,2'-azobisisobutyronitrile; aluminium acetylacetonate; heptane; acrylates copolymer; ethylene distearamide; adipic acid/1,4-butanediol/mdi copolymer; pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate - buprenorphine sandoz patches are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. buprenorphine sandoz patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. buprenorphine sandoz patches are not indicated as an as-needed (prn) analgesia.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - lacosamide, quantity: 150 mg - tablet, film coated - excipient ingredients: crospovidone; hyprolose; colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black - lacosamide sandoz (lacosamide) tablets are indicated as: ? monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. ? add-on therapy in the treatment of partial onset seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older. ? add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older.,paediatric patents weighing less than 50 kg should not receive lacosamide sandoz film-coated tablets. paediatric patients weighing less than 50 kg should be accurately dosed on a mg/kg basis with other lacosamide products.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - lacosamide, quantity: 50 mg - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; colloidal anhydrous silica; crospovidone; hyprolose; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black; indigo carmine aluminium lake - lacosamide sandoz (lacosamide) tablets are indicated as: ? monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. ? add-on therapy in the treatment of partial onset seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older. ? add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older.,paediatric patents weighing less than 50 kg should not receive lacosamide sandoz film-coated tablets. paediatric patients weighing less than 50 kg should be accurately dosed on a mg/kg basis with other lacosamide products.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - lacosamide, quantity: 100 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; hyprolose; crospovidone; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - lacosamide sandoz (lacosamide) tablets are indicated as: ? monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. ? add-on therapy in the treatment of partial onset seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older. ? add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older.,paediatric patents weighing less than 50 kg should not receive lacosamide sandoz film-coated tablets. paediatric patients weighing less than 50 kg should be accurately dosed on a mg/kg basis with other lacosamide products.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - lacosamide, quantity: 200 mg - tablet, film coated - excipient ingredients: hyprolose; microcrystalline cellulose; crospovidone; colloidal anhydrous silica; magnesium stearate; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350; indigo carmine aluminium lake - lacosamide sandoz (lacosamide) tablets are indicated as: ? monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. ? add-on therapy in the treatment of partial onset seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older. ? add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older.,paediatric patents weighing less than 50 kg should not receive lacosamide sandoz film-coated tablets. paediatric patients weighing less than 50 kg should be accurately dosed on a mg/kg basis with other lacosamide products.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - pirfenidone, quantity: 801 mg - tablet - excipient ingredients: pregelatinised starch; croscarmellose sodium; hyprolose; magnesium stearate; silicon dioxide; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black - pirfenidone sandoz is indicated for the treatment of idiopathic pulmonary fibrosis (ipf).

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - pirfenidone, quantity: 267 mg - tablet - excipient ingredients: hyprolose; silicon dioxide; croscarmellose sodium; magnesium stearate; pregelatinised starch; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - pirfenidone sandoz is indicated for the treatment of idiopathic pulmonary fibrosis (ipf)

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - sunitinib, quantity: 50 mg - capsule - excipient ingredients: magnesium stearate; microcrystalline cellulose; gelatin; povidone; iron oxide red; mannitol; titanium dioxide; croscarmellose sodium; iron oxide black; iron oxide yellow; propylene glycol; butan-1-ol; isopropyl alcohol; ethanol; shellac; strong ammonia solution; sulfuric acid - ? treatment of advanced renal cell carcinoma (rcc),? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance,? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - sunitinib, quantity: 37.5 mg - capsule - excipient ingredients: povidone; croscarmellose sodium; titanium dioxide; magnesium stearate; microcrystalline cellulose; gelatin; mannitol; iron oxide yellow; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; strong ammonia solution; ethanol absolute; iron oxide black; ethanol; shellac; sulfuric acid - ? treatment of advanced renal cell carcinoma (rcc),? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance,? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).